Shenouda Maged purchased $844K of RLMD
Shenouda Maged (Chief Financial Officer) purchased 200,000 shares of RELMADA THERAPEUTICS, INC. (RLMD) at an average of $4.22 ($4.20–$4.25, $0.84M total) across 2 trades over 2026-09-09 to 2026-09-10.
How this was made
The 30-second read
Why it matters
The CFO's purchase adds to his ownership, indicating personal confidence, but the modest size limits market reaction.
Market read
Primary insider purchase filing; modest size suggests limited immediate trading impact.
What to watch
Potential upcoming clinical data releases or financing events not disclosed in this filing.
Background
Form 4 disclosures provide transparent reporting of insider transactions required by the SEC.
Ticker impact
CFO Shenouda Maged purchased 200,000 shares for $844K, increasing his stake to 1,000,000 shares.
Potential slight upside pressure if market perceives confidence, but limited effect.
The purchase is a primary Form 4 filing, providing new information, yet the dollar size is under $1M, reducing material impact.
Market effects
Minimal; biotech sector may note insider confidence but no broader shift.
U.S. market only, no regional ripple.
Low; limited to RLMD investors.
Counterpoint
Insider purchase could be routine portfolio rebalancing rather than a bullish signal.
Key entities
- PersonShenouda Maged
Chief Financial Officer of Relmada Therapeutics
- CompanyRelmada Therapeutics, Inc.
Biopharmaceutical company developing treatments for neuropsychiatric disorders
